Free Trial
→ Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX (From InvestorPlace) (Ad)tc pixel
NASDAQ:SLRN

Acelyrin Q1 2024 Earnings Report

Acelyrin logo
ProfileEarnings History

Acelyrin EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.93
Beat/Miss
Beat by +$0.57
One Year Ago EPS
N/A

Acelyrin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Acelyrin Announcement Details

Quarter
Q1 2024
Date
5/14/2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
4:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Acelyrin's Q1 2024 Quarterly reportQuarterly report
(10-Q)

Acelyrin Earnings Headlines

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
May 13, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/13/3080506/0/en/acelyrin-stockholders-approve-merger-with-alumis-to-create-clinical-biopharma-company-dedicated-to-innovating-developing-and-commercializing-transformative-therapies-for-immune-med.html
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
May 6, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/06/3075586/0/en/leading-independent-proxy-advisory-firm-iss-recommends-acelyrin-stockholders-vote-for-the-proposed-transaction-with-alumis.html
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.tc pixel
May 6 at 1:00 AM  |  Profits Run (Ad)
Acelyrin urges stockholders to vote for proposed merger with Alumis
May 2, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/acelyrin-urges-stockholders-vote-proposed-174551144.html
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
May 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/01/3072714/0/en/acelyrin-reiterates-benefits-of-value-maximizing-combination-with-alumis.html
Alumis and ACELYRIN Announce Amended Merger Agreement
April 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/21/3064525/0/en/alumis-and-acelyrin-announce-amended-merger-agreement.html
See More Acelyrin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Acelyrin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acelyrin and other key companies, straight to your email.

About Acelyrin

Acelyrin (NASDAQ:SLRN), a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

View Acelyrin Profile
Earnings Tools